The FDA of the American pharmaceutical authority has approved an injection of HIV prevention. The average Lenacapavir only needs to be injected twice a year and is intended to offer 99.9 percent protection. It is unclear when the HIV prevention can be admitted to the EU.
On Wednesday (local time), the FDA Lenacapavir approved the pharmaceutical company Gilead, which, according to this infection protection, offers 99.9 percent. Unlike other medicines, Lenacapavir only has to be injected twice a year. Possible side effects are responses to the injection site, headache and nausea.
Price still very high at the moment
With a good $ 28,000 (around 24,000 euros) per person per year, Lenacapavir is still very expensive. However, experts appreciate the production costs at only $ 40. It is unclear when HIV prevention can be admitted to the EU.
Lenacapavir is already used in HIV therapy. The drug is mainly given to people who have had hi viruses for a long time and have to deal with resistance to other medication.
License contracts with generic manufacturers
In October 2024, Gilead announced the conclusion of license contracts with six generic manufacturers, who now have to produce and sell the fund in countries with low incomes.
However, critics point out that millions of HIV-infected people live in countries in which such a cheaper version of Lenacapavir will not be available for the time being.
Source: Krone
I am an experienced and passionate journalist with a strong track record in news website reporting. I specialize in technology coverage, breaking stories on the latest developments and trends from around the world. Working for Today Times Live has given me the opportunity to write thought-provoking pieces that have caught the attention of many readers.
